Shikari® (QS-VEDO)

Enzyme immunoassay for the specific and quantitative determination of free Vedolizumab (Entyvio®) in serum and plasma.

This kit has been especially developed for the specific and quantitative determination of free vedolizumab (Entyvio®) in serum and plasma samples between the Cmin and Cmax range of concentrations.

Vedolizumab Drug Bank Accession Number is DB09033

Vedolizumab is an integrin blocker and anti-inflammatory agent used to manage ulcerative colitis and Crohn’s disease in adults with inadequate clinical response to immunomodulators.Vedolizumab is a recombinant humanized IgG1 monoclonal antibody directed against the human lymphocyte α4β7 integrin, a key mediator of gastrointestinal inflammation. It is used in the treatment of moderate to severe active ulcerative colitis and Crohn’s disease for patients who have had an inadequate response with, lost response to, or were intolerant to inhibitors of tumor necrosis factor-alpha (TNF-alpha) or other conventional therapies.

Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.